Latest News
Nov 9, 2018

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug...

Nov 5, 2018

Mylan N.V. (NASDAQ: MYL) today announced its financial results for the quarter and nine months ended September 30, 2018. Third Quarter 2018 Financial Highlights U.S. GAAP diluted earnings per...

Oct 22, 2018

Oct. 22, 2018 In response to multiple inquiries received regarding the status of Mylan’s Abbreviated New Drug Application for generic Advair® (Wixela®), Mylan confirms it has not received any...

Oct 19, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has initiated the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets...

Oct 19, 2018

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a...

View More

Search News Releases

Contact Mylan Communications

Global Communications 

Stay Connected